GlassScriptPhysician profile
Anil Shah
NPI 1730108069
$4,472.49
in general payments reported to CMS, 2019-2025
29 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $245 · 2021: $626 · 2022: $577 · 2023: $780 · 2024: $578 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.21 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $565.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $530.51 | 2021-2025 | Verquvo, Belsomra |
| Amgen INC. | $490.76 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $407.56 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $384.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.15 | 2019-2025 | Jardiance |
| Medtronic, INC. | $306.51 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $227.93 | 2019-2024 | |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Atricure, INC. | $173.45 | 2022-2025 | Atriclip Laa Exclusion System |
| Janssen Pharmaceuticals, INC | $141.71 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $139.85 | 2019-2025 | Farxiga |
| Genzyme Corporation | $125.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $110.49 | 2019 | |
| Boston Scientific Corporation | $58.20 | 2019-2025 | Cds - Mct/Cem Monitoring |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.40 | 2020-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $38.03 | 2025 | |
| Lilly USA, LLC | $28.79 | 2025 | Mounjaro, Zepbound |
| Irhythm Technologies, INC. | $24.37 | 2023 | Zio Xt Patch |
| Lexicon Pharmaceuticals, INC. | $20.94 | 2023 | Inpefa |
| Mallinckrodt Hospital Products INC. | $20.11 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $20.03 | 2019 | |
| Allergan, INC. | $19.59 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.83 | 2020 | |
| Celgene Corporation | $15.79 | 2019 | |
| Tandem Diabetes Care, INC. | $15.01 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.82 | 2021 | |
| Gilead Sciences, INC. | $13.33 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.